Cargando…
S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity
Liver-related autoimmune toxicities triggered by agonistic anti-CD137 antibodies have greatly limited their use in clinical applications. Here, we found that anti-CD137 monoclonal antibody (mAb) treatment in mice induced the infiltration of a large number of S100A4(+) macrophages into the liver. Dep...
Autores principales: | Zhang, Jinhua, Song, Kun, Wang, Jun, Li, Yanan, Liu, Shuangqing, Dai, Chengliang, Chen, Lieping, Wang, Shengdian, Qin, Zhihai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889198/ https://www.ncbi.nlm.nih.gov/pubmed/29632708 http://dx.doi.org/10.1080/2162402X.2017.1296996 |
Ejemplares similares
-
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014) -
CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022) -
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022) -
Extracellular S100A4 as a key player in fibrotic diseases
por: Li, Zhenzhen, et al.
Publicado: (2020) -
S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness
por: Li, Yanan, et al.
Publicado: (2020)